CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest	Total
Balance at beginning of period at Dec. 31, 2017	$ 725.4	$ 1.7	$ (401.2)	$ 155.9	$ 942.0	$ 27.0	$ 8.1	$ 0.0	$ 733.5
Balance (in shares) at Dec. 31, 2017		155,865,977	16,009,099
Increase (Decrease) in Stockholders' Equity
Restricted shares terminated (in shares)		(6,553)	6,553
Stock options exercised	10.3			10.3					10.3
Stock options exercised (in shares)		575,372
RSU vested	(0.6)			(0.6)					(0.6)
RSU vested (in shares)		183,772
Shares returned for acquisition	0.1		$ 0.1						0.1
Shares returned for acquisition (in shares)		(2,123)	2,123
Distributions to noncontrolling interests							(0.9)		(0.9)
Stock based compensation	11.3			11.3					11.3
Cash dividends paid to common stockholders	25.1				25.1				25.1
Acquired 80% interest in Hain LifeScience GmbH								23.2
Consolidated net income	179.7				179.7		1.3	(0.2)	181.0
Treasury stock acquired	(0.2)		$ (0.2)						(0.2)
Treasury stock acquired (in shares_		(7,105)	7,105
Other comprehensive income (loss)	(10.0)					(10.0)	(0.2)	(0.4)	(10.2)
Balance at end of period at Dec. 31, 2018	896.6	$ 1.7	$ (401.5)	176.9	1,102.5	17.0	8.5	22.6	905.1
Balance (in shares) at Dec. 31, 2018		156,609,340	16,024,880
Increase (Decrease) in Stockholders' Equity
Effect period of adoption new accounting principle | ASC 606	5.9				5.9		0.2		6.1
Stock options exercised	12.0			12.0					12.0
Stock options exercised (in shares)		626,796
RSU vested	(1.1)			(1.1)					(1.1)
RSU vested (in shares)		241,359
Stock based compensation	11.9			11.9					11.9
Cash dividends paid to common stockholders	25.0				25.0				25.0
Consolidated net income	197.2				197.2		1.9	(1.1)	199.1
Shares repurchased	(142.3)		$ (142.3)						(142.3)
Shares repurchased (in shares)		(3,323,104)	3,323,104
Treasury stock acquired	(0.1)		$ (0.1)						(0.1)
Treasury stock acquired (in shares_		(1,680)	1,680
Shares issued for acquisition	0.1		$ 0.1						0.1
Shares issued for acquisition (in shares)		3,087	(3,087)
Other comprehensive income (loss)	(42.5)					(42.5)	(0.1)	(0.4)	(42.6)
Balance at end of period at Dec. 31, 2019	906.8	$ 1.7	$ (543.8)	199.7	1,274.7	(25.5)	10.3	21.1	917.1
Balance (in shares) at Dec. 31, 2019		154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	4.9			4.9					4.9
Stock options exercised (in shares)		241,915
RSU vested	(1.6)			(1.6)					(1.6)
RSU vested (in shares)		301,320
Distributions to noncontrolling interests							(1.2)		(1.2)
Stock based compensation	13.3			13.3					13.3
Cash dividends paid to common stockholders	24.7				24.7				24.7
Acquired 80% interest in Hain LifeScience GmbH	(1.3)				(1.3)			(20.6)	(1.3)
Consolidated net income	157.8				157.8		3.6		161.4
Shares repurchased	(123.2)		$ (123.2)						(123.2)
Shares repurchased (in shares)		(2,711,952)	2,711,952
Other comprehensive income (loss)	29.2					29.2	0.4	$ (0.5)	29.6
Balance at end of period at Dec. 31, 2020	$ 961.2	$ 1.7	$ (667.0)	$ 216.3	$ 1,406.5	$ 3.7	$ 13.1		$ 974.3
Balance (in shares) at Dec. 31, 2020		151,987,081	22,058,529